{
}
Insilico Medicine, an AI-driven drug discovery company, has raised $110 million in its Series E funding round, achieving a valuation of over $1 billion. The investment, led by Value Partners Group, will enhance its AI platform and support the clinical development of Rentosertib for idiopathic pulmonary fibrosis, which has completed Phase IIa trials.With a pipeline of 30 drug assets, including 10 approved by the US FDA for investigational use, Insilico also licenses its assets to firms like Fosun Pharma and Exelixis, securing contracts worth approximately $3.5 billion. The company is advancing its proprietary AI system, “pharma.ai,” and developing humanoid robots to automate lab processes.
Investors are keenly observing advancements in Alzheimer’s disease treatments, with significant interest expected in 2025. Companies like Biogen and Eli Lilly have invested heavily in potential therapies, while others such as Novo Nordisk and Roche are also exploring this area. Breakthroughs could significantly influence share prices, as the market is projected to reach $13 billion by 2030, according to Bloomberg Intelligence.
Novo Nordisk received an upgrade from UBS, moving from “Neutral” to “Buy,” despite challenges from Eli Lilly's more effective weight loss drug, tirzepatide. While Novo's semaglutide drugs, Ozempic and Wegovy, have lower weight loss results, they benefit from stronger brand recognition. The recent stock sell-off related to their experimental drug Carigsema was deemed excessive, presenting a favorable entry point for investors.
Sandoz Group AG plans to launch a generic version of Ozempic in Canada by 2026, targeting the growing demand for GLP-1 weight-loss drugs amid high prices for branded options. The company is investing in production to ensure a reliable supply of semaglutide, the active ingredient, as it anticipates significant market potential if prices decrease. With obesity affecting one in three Canadian adults, Sandoz aims to make these effective treatments more accessible.
Sandoz Group AG is set to launch a generic version of Ozempic in Canada by 2026, aiming to challenge Novo Nordisk A/S. The Swiss company anticipates strong demand for GLP-1 weight-loss drugs, particularly generics, due to the high costs of branded options, despite competition from Novo and Eli Lilly & Co.
Sandoz Group AG is set to launch a generic version of Ozempic in Canada by 2026, aiming to compete with Novo Nordisk A/S. The Swiss company anticipates strong demand for GLP-1 weight-loss drugs, particularly due to the high costs of branded options, despite advancements from competitors like Eli Lilly & Co.
Eli Lilly & Co. has approved a $15 billion share buyback program, driven by significant growth from its weight-loss drug Zepbound. Additionally, the company announced a 15% increase in its quarterly dividend, leading to a 1.3% rise in shares during after-hours trading.
[Bloomberg](https://www.bloomberg.com) and [SEC]
Eli Lilly & Co. is investing $3 billion to expand its U.S. manufacturing capabilities to meet the rising demand for its diabetes and weight-loss medications. The investment will enhance a recently acquired production facility in Wisconsin, with construction set to begin next year. This expansion aims to boost the supply of injectable drugs like Mounjaro and Zepbound.
Stocks reached record highs as Federal Reserve Chair Jerome Powell expressed optimism about the U.S. economy, with the S&P 500 and Nasdaq 100 both climbing. Despite a strong market, concerns about potential corrections linger, as geopolitical tensions and a slower Fed rate-cutting cycle could impact future performance. Investors are hopeful for a December rally, but caution is advised given the recent gains and market dynamics.
Eli Lilly & Co
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Insilico Medicine secures 110 million dollars in series E funding round
United States Dollar
FOSUN PHARM
Eli Lilly & Co
Exelixis, Inc.
Value Partners Group Ltd
Orbimed Advisors LLC
USA
CHN
Eli Lilly
Show more
04:50 13.03.2025
investors eye alzheimer's drug breakthroughs for potential market gains
06:00 10.01.2025
novo nordisk upgraded as competition intensifies in weight loss drug market
20:06 08.01.2025
sandoz plans generic ozempic launch in canada by 2026
Canadian Dollar
Sandoz Group AG
Eli Lilly & Co
Novo Nordisk A/S
CHN
USA
CAN
Richard Saynor
Show more
13:49 11.12.2024
sandoz plans generic ozempic launch in canada by 2026
13:12 11.12.2024
sandoz plans generic ozempic launch in canada by 2026
13:12 11.12.2024
lilly announces 15 billion share buyback and dividend increase
22:46 09.12.2024
Stocks Retreat Ahead of Key Jobs Data as Market Anxiety Grows
United States Dollar
Euro
British Pound Sterling
Japanese Yen
Canadian Imperial Bank of Commerce
The Toronto-Dominion Bank
Southwest Airlines Co.
American Airlines Group Inc.
Dollar General Inc.
Eli Lilly & Co
Boeing Co
Bank of Montreal
The Kroger Co.
USA
Oscar Munoz
Gennadiy Goldberg
Keith Gill
Dennis Debusschere
Matthew Weller
Donald Trump
Chris Larkin
Show more
22:11 05.12.2024
Lilly Invests 3 Billion to Expand Weight Loss Drug Manufacturing in US
21:30 05.12.2024
US Markets Rally Continues Amid Strong Consumer Sentiment and Economic Outlook
United States Dollar
Euro
British Pound Sterling
Japanese Yen
UnitedHealth Group Inc
JetBlue Airways Corp
Dollar Tree Inc
Royal Bank of Canada
General Motors Co
Foot Locker Inc
Eli Lilly & Co
Nippon Steel Corp
USA
Jerome Powell
Marine Le Pen
Calli Cox
Brian Thompson
Andrew Adams
Callum Thomas
Mark Hackett
Show more
22:09 04.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Workplace Trends
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Domestic Politics
Government Policies
Global Trade Developments
Startups & Entrepreneurship
Central Bank Actions
Elections & Campaigns
Government Economic Policies
Financial Scams and Security
Corporate Social Responsibility
Countries:
Companies:
Tesla, Inc.
JPMorgan Chase & Co.
Barclays PLC
UniCredit S.p.A.
Deutsche Bank Money Market PP
Banco BPM S.p.A.
Credit Suisse Lux Digital Healt
Bank of America Corporation
Apple Inc.
UBS Group AG
BNP Paribas SA
The Goldman Sachs Group, Inc.
Commerzbank AG
CREDIT AGRICOLE
Credit Suisse Strategic Income I
Lloyds Banking Group plc
Wells Fargo & Company
Banco Santander, S.A.
SpaceXCoin USD
Amazon.com, Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Canadian Dollar
Mexican Peso
Singapore Dollar
Norwegian Krone
Filipino Peso
Indonesian Rupiah
Russian Ruble
Chilean Peso
People: